Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 35.21% is 17% above its 5-year average of 30.02%, around the middle of its 5-year range (14.47%–45.49%).
10.52% above its 12-month average of 31.86%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-06-30): 21.83%.
EBITDA MARGIN
35.21%
EBITDA MARGIN AVG TTM
31.86%
EBITDA MARGIN AVG 3Y
26.26%
EBITDA MARGIN AVG 5Y
30.02%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+10.52%
CURRENT VS 3Y AVG
+34.08%
CURRENT VS 5Y AVG
+17.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$348.59M
EBITDA Margin
-25837.05%
TTM Avg
-12960.93%
3Y Avg
-7440.06%
5Y Avg
-7440.06%
Market Cap
$345.48M
EBITDA Margin
-59.31%
TTM Avg
-58.08%
3Y Avg
-69.87%
5Y Avg
-66.91%
Market Cap
$361.64M
EBITDA Margin
-271.53%
TTM Avg
-418.08%
3Y Avg
-211.46%
5Y Avg
-940.00%
Market Cap
$366.39M
EBITDA Margin
-122.86%
TTM Avg
-149.66%
3Y Avg
-152.47%
5Y Avg
-125.05%
Market Cap
$330.60M
EBITDA Margin
-285.23%
TTM Avg
-308.13%
3Y Avg
-415.00%
5Y Avg
-335.56%
Market Cap
$329.01M
EBITDA Margin
-184.07%
TTM Avg
-174.53%
3Y Avg
-153.81%
5Y Avg
-153.81%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $348.85M | 35.21% | 31.86% | 26.26% | 30.02% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -25837.05% | -12960.93% | -7440.06% | -7440.06% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -59.31% | -58.08% | -69.87% | -66.91% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -271.53% | -418.08% | -211.46% | -940.00% |
| Agenus Inc. (AGEN)vs › | $363.54M | -9.24% | -56.39% | -95.53% | -82.66% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -122.86% | -149.66% | -152.47% | -125.05% |
| C4 Therapeutics, Inc. (CCCC)vs › | $330.60M | -285.23% | -308.13% | -415.00% | -335.56% |
| CapsoVision, Inc. (CV)vs › | $329.01M | -184.07% | -174.53% | -153.81% | -153.81% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | -13.98% | -3.54% | -384.69% | -2364.58% |
Gross Margin
59.9%
EBITDA Margin
35.2%
Operating Margin
24.9%
Net Margin
8.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 21.83% |
| 2026-03-31 | 25.11% |
| 2025-12-31 | 42.11% |
| 2025-09-30 | 30.34% |
| 2025-06-30 | 39.90% |
| 2025-03-31 | 34.83% |
| 2024-12-31 | 33.91% |
| 2024-09-30 | 15.94% |
| 2024-06-30 | 24.59% |
| 2024-03-31 | 17.20% |
| 2023-12-31 | 20.41% |
| 2023-09-30 | 14.47% |
| 2023-06-30 | 20.76% |
| 2023-03-31 | 22.95% |
| 2022-12-31 | 34.82% |
| 2022-09-30 | 25.67% |
| 2022-06-30 | 36.48% |
| 2022-03-31 | 38.47% |
| 2021-12-31 | 43.21% |
| 2021-09-30 | 41.86% |
| 2021-06-30 | 45.49% |
| 2021-03-31 | 48.06% |
| 2020-12-31 | 46.76% |
